27771-25-1

Usage

Uses

Used in Pharmaceutical Research and Development:
1-Benzyl-4-hydroxypiperidine-4-carboxamide is used as a compound of interest for pharmaceutical research and development due to its potential biological activities and structural features. Its exploration in this field could lead to the discovery of new drugs or therapeutic agents.
Used in Chemical Synthesis:
1-Benzyl-4-hydroxypiperidine-4-carboxamide is used as a starting material or intermediate in the synthesis of more complex molecules for various applications, including pharmaceuticals, agrochemicals, or other specialty chemicals. Its unique structure may allow for the creation of novel compounds with desired properties.
Used in Academic Research:
1-Benzyl-4-hydroxypiperidine-4-carboxamide is used as a subject of study in academic research to understand its chemical properties, reactivity, and potential interactions with biological systems. This research could provide insights into its potential applications and help guide further development in the pharmaceutical industry.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 71617-20-4 1-benzyl-4-hydroxy-4-piperidinecarbonitrile hydrochloride 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 

Downstream Products

• 27759-94-0 8-benzyl-2-thiophen-2-yl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 25506-03-0 8-benzyl-2-(4-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27759-87-1 8-benzyl-2-(2-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-28-2 2-(3-fluoro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27759-99-5 2-(3-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-27-1 2-(4-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27759-98-4 2-(2-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27760-01-6 2-(4-methoxy-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 25506-07-4 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2,2-dimethyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27760-02-7 3-[4-(4-fluoro-phenyl)-4-oxo-butyl]-7-oxa-3,14-diaza-dispiro[5.1.5.2]pentadecan-15-one 
• 27810-31-7 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-phenyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 25506-08-5 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-m-tolyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27771-48-8 2-benzyl-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-methyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-35-1 2-(3-fluoro-phenyl)-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 

Relevant academic research and scientific papers

ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF

A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES

4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.

3-SUBSTITUTED-6-ARYL PYRIDINES

3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

Phthalazine derivatives and remedies for erectile dysfunction

The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1and R2are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1is a chlorine atom, R2is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.